Efficacy and tolerance of aranoza combined with topotecan against transplantable lung cancer on mice
New nitro urea anticancer drug aranoza (<i>Ar</i>) was administered simultaneously with topotecan (<i>T</i>) to BDF1 mice bearing s.c. Lewis lung carcinoma (LLC) or Balb/c nude mice bearing human s.c. lung cancer xenografts RL4 (cell line A549). <i>T </i>was injected with doses of 0.5; 0.75; 1.0 or 2.0 mg/kg 3 times daily or 2.5; 5.0; 10.0 mg/kg on day 2 after LLC transplantation. The same it was for <i>T </i>dose range of 0.5 mg/kg 2 times on days 2 and 4 after RL4 inoculation. For Ar, dose range was the following: of 100 or 200 mg/kg 3 times daily after LLC inoculation or 100 mg/kg 2 times on days 2 and 4 after RL4 inoculation. All drugs were given i.p. Synergism of <i>TAr </i>was demonstrated in comparison with monotherapy of <i>T </i>and <i>Ar</i>. The therapeutic efficacy and tolerance of <i>TAr </i>in comparison with standard second-line monotherapy <i>T </i>were evaluated.